news | Synthekine - Part 2

Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes

February 20, 2024/in 2024, news/by eallison

February 21, 2024

Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases

January 25, 2024/in 2024, news/by eallison

January 29, 2024

Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window

November 2, 2023/in 2023, news/by eallison

November 3, 2023

First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors

September 27, 2023/in 2023, news/by David Anderson

September 28, 2023

Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies

July 26, 2023/in 2023, news/by David Anderson

July 27, 2023

Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs

April 11, 2023/in 2023, news/by David Anderson

April 12, 2023

Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics

January 5, 2023/in 2023, news/by David Anderson

January 6, 2023

Fierce Biotech names Synthekine as one of its “Fierce 15” Biotech Companies of 2022

September 12, 2022/in 2022, news/by David Anderson

September 12, 2022

Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting

April 7, 2022/in 2022, news/by David Anderson

April 7, 2022

Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors

February 3, 2022/in 2022, news/by David Anderson

February 3, 2022